Treatment of paroxysmal atrial fibrillation with pill-in-the-pocket approach-comparison of propafenone and flecainide
- Conditions
- Recent-onset atrial fibrillation
- Registration Number
- JPRN-UMIN000004553
- Lead Sponsor
- Fujita Health University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
Patients were excluded if they had one or more of the following findings: electrocardiographic evidence of ventricular pre-excitation or bundlebranch block (QRS interval >120 msec), a previous episode of atrial fibrillation lasting seven days or more, ischemic heart disease, dilated or hypertrophic cardiomyopathy, a history of heart failure, severe valvular heart disease, chronic cor pulmonale, left ventricular dysfunction (ejection fraction, 50 percent), a long QT interval or the Brugada syndrome, the bradycardia-tachycardia syndrome (resting heart rate, 50 beats per minute, or repetitive sinoatrial blocks during waking hours), documentation of previous episodes of second or third-degree atrioventricular block, previous thromboembolic episodes, acute disease, very severe chronic diseases (e.g., muscular dystrophies or systemic collagen diseases), renal or hepatic insufficiency, previous hypokalemia (potassium level, <3 mmol per liter), suspected or known pregnancy, a known intolerance of flecainide or current propafenone, or current prophylactic antiarrhythmic treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Termination of atrial fibrillation within 120 min after treatment of propafenone or flecainide
- Secondary Outcome Measures
Name Time Method Safety (blood pressure and proarrhythmia) Plasma drug concentration